Skip to content
DataLookout
Menu

NCT06688058

A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved 60 days later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 9 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 4 words
    • Primary and study completion pushed from Nov 30, 2026 to Jan 29, 2027
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 4 of 4 sites
    v9
  3. Minor Site details revised at 3 of 4 sitesv8
  4. Minor Primary and study completion dates: Aug 20, 2027 to Nov 30, 2026v6
  5. Notable Primary and study completion dates: Feb 12, 2027 to Aug 20, 2027
    • Study sites: 1 to 4
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Minor Primary and study completion dates: Jan 6, 2027 to Feb 12, 2027v4
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 12, 2024 to Dec 20, 2024
    v3
  3. Notable Eligibility criteria expanded, about 19 wordsv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants Who Experience a Solicited Injection-Site Adverse Event (AE)
Timeframe: Up to approximately 6 months
Number of Participants Who Experience a Solicited Systemic AE
Timeframe: Up to approximately 6 months
Number of Participants Who Experience Immediate Reactions Occurring Within 30 Minutes After Any Vaccination
Timeframe: Up to approximately 6 months
Number of Participants Who Experience Unsolicited AEs
Timeframe: Up to approximately 7 months
Number of Participants Who Experience a Serious Adverse Event (SAE)
Timeframe: Up to approximately 18 months
Number of Participants Who Experience a Medically-Attended AE (MAAE)
Timeframe: Up to approximately 18 months
Number of Participants Who Experience an Event of Clinical Interest (ECI)
Timeframe: Up to approximately 18 months

Secondary (1)

Total Immunoglobulin G (IgG) Geometric Mean Ratios (GMRs) for anti-HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58

Arms and interventions

V540DExperimental

Participants will receive vaccinations with V540D.

GARDASIL®9Active comparator

Participants will receive vaccinations with GARDASIL®9.

Biologicals: V540D, GARDASIL®9

Sites

4 sites in 1 country